Vimarsana
Biggest News Aggregation in the World

Page 8 - Initial Public News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Initial Public. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Initial Public Today - Breaking & Trending Today

BRERA : INDEX TO CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K -December 29, 2023 at 04:39 pm EST - Vimarsana News

BRERA : INDEX TO CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K -December 29, 2023 at 04:39 pm EST

BRERA HOLDINGS PLC INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Consolidated Financial Statements for the Six Months...

Stocks to Watch: Azad Engineering, SBI, Zomato, Bata, Adani Shares, Paytm, and Others - Vimarsana News

Stocks to Watch: Azad Engineering, SBI, Zomato, Bata, Adani Shares, Paytm, and Others

Stocks to watch: Shares of firms like Azad Engineering, SBI, Zomato, Bata, Adani Shares, Paytm, and others will be in focus on Thursday's trade.

Source: news18.com
Turbo Energy S A : INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS TURBO ENERGY, S.A - Form 6-K -December 22, 2023 at 05:20 pm EST - Vimarsana News

Turbo Energy S A : INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS TURBO ENERGY, S.A - Form 6-K -December 22, 2023 at 05:20 pm EST

INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS TURBO ENERGY, S.A. Condensed Interim Consolidated Financial Statements ...

innova captab: Innova Captab's Rs 570-cr IPO to open on Dec 21 - Vimarsana News

innova captab: Innova Captab's Rs 570-cr IPO to open on Dec 21

The maiden public issue comprises a fresh issue of equity shares worth up to Rs 320 crore and an offer-for-sale (OFS) of up to 55.80 lakh equity shares by promoters and selling shareholders.

Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights - Vimarsana News

Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

Completed enrollment of the LEAD Phase 1/2 clinical trial of LX1001 for the treatment of APOE4-associated Alzheimer’s disease